Advertisement

Psychopharmacology

, Volume 96, Issue 3, pp 385–390 | Cite as

Acute barbiturate administration increases benzodiazepine receptor binding in vivo

  • Lawrence G. Miller
  • Stephen I. Deutsch
  • David J. Greenblatt
  • Steven M. Paul
  • Richard I. Shader
Original Investigations

Abstract

Barbiturates have been reported to augment benzodiazepine receptor affinity in vitro, but their effects in vivo are uncertain. We determined benzodiazepine receptor binding in vivo by specific uptake of [3H]Ro15-1788 after barbiturate administration. Pentobarbital (30 mg/kg) increased receptor binding in cerebral cortex and cerebellum at 30 min after injection, with a peak effect occurring at 1 h after dosage, and a return to control levels at 2 h. Specific binding was increased at 1 h after pentobarbital administration in a dose-dependent fashion (7.5–90 mg/kg). Pentobarbital at doses up to 30 mg/kg failed to alter nonspecific binding, but at doses of 60 mg/kg increases in nonspecific binding were observed. The increases in specific binding observed after barbiturate administration were most likely due to a change in apparent receptor affinity, as determined by administration of varying doses of clonazepam to pentobarbital-treated (30 mg/kg) animals. The order of potency of a series of barbiturates in augmenting benzodiazepine receptor binding in cerebral cortex and cerebellum in vivo was: secobarbital>pentobarbital>amobarbital>phenobarbital>barbital. The same relative rank order of potency exists for the anesthetic/hypnotic activity of these barbiturates. These data suggest that barbiturates increase the apparent affinity of benzodiazepine receptors in vivo; unlike their in vitro actions, these alterations can be detected with a receptor antagonist.

Key words

Barbiturates Benzodiazepines Receptors Pentobarbital Phenobarbital 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Albrecht RF, Cook J, Hoffman WE, Larschied P, Miletich DJ, Naughton N (1985) The interaction between benzodiazepine antagonists and barbiturate-induced cerebrovascular and cerebral metabolic depression. Neuropharmacology 24:957–963Google Scholar
  2. Barker JL, Owen DG, Segal M (1984) GABA actions on the excitability of cultured CNS neurons. Neurosci Lett 47:313–318Google Scholar
  3. Chweh AY, Ulloque RA, Swinyard WA, Wolf HH (1985) Effect of picrotoxinin on benzodiazepine receptor binding. Neurochem Res 10:871–877Google Scholar
  4. Costa T, Rodbard D, Pert CB (1979) Is the benzodiazepine receptor coupled to a chloride channel? Nature 277:315–317Google Scholar
  5. Davis WC, Ticku MK (1981) Pentobarbital enhances [3H]-diazepam binding to soluble receptors at the benzodiazepine-GABA-receptor-ionophore complex. Neurosci Lett 23:209–213Google Scholar
  6. Fisher TE, Tuchek JM, Johnson DD (1986) A comparison of methods for removal of endogenous GABA from brain membranes prepared for binding assays. Neurochem Res 11:1–8Google Scholar
  7. Gallagher JP, Nakamura J, Inokuchi H, Shinnick-Gallagher P (1981) Effects of anticonvulsants on excitability and GABA sensitivity of cat dorsal root ganglion cells. Neuropharmacology 20:427–433Google Scholar
  8. Goeders NE, Kuhar MJ (1985) Benzodiazepine receptor binding in vivo with [3H]-Ro15–1788. Life Sci 37:345–355Google Scholar
  9. Haefely W, Kyburz E, Gerecke M, Möhler H (1985) Recent advances in the molecular pharmacology of benzodiazepine receptors and in the structure-activity relationships of their agonists and antagonists. Adv Drug Res 14:165–322Google Scholar
  10. Harvey SC (1985) Hypnotics and sedatives. In: Goodman LS, Gilman A, Rall TW, Murad F (eds) The pharmacological basis of therapeutics. 7th edn. Macmillan, New York, pp 339–371Google Scholar
  11. Holford NHG, Sheiner LB (1981) Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 6:429–453Google Scholar
  12. Iadarola MJ, Fanelli RJ, McNamara JO, Wilson WA (1985) Comparison of the effects of diphenylbarbituric acid, phenobarbital, pentobarbital and secobarbital on GABA-mediated inhibition and benzodiazepine binding. J Pharmacol Exp Ther 232:127–133Google Scholar
  13. Jakoby W (1962) GABA. Methods Enzymol v:777–780Google Scholar
  14. Koe BK, Kondratas EL, Russo LL (1987) [3H]-Ro15–1788 binding to benzodiazepine receptors in mouse brain in vivo: marked enhancement by GABA agonists and other CNS drugs. Eur J Pharmacol 142:373–384Google Scholar
  15. Leeb-Lundberg F, Olsen RW (1982) Interactions of barbiturates of various pharmacological categories with benzodiazepine receptors. Mol Pharmacol 21:320–328Google Scholar
  16. Leeb-Lundberg F, Snowman A, Olsen RW (1980) Barbiturate receptor sites are coupled to benzodiazepine receptors. Proc Natl Acad Sci USA 77:7468–7472Google Scholar
  17. Lister RG, Greenblatt DJ, Abernethy DR, File FE (1984) Pharmacokinetic studies on Ro15–1788, a benzodiazepine receptor ligand, in the brain of the rat. Brain Res 290:183–186Google Scholar
  18. MacDonald RL, Barker JL (1979) Anticonvulsants and anesthetic barbiturates. Neurology 29:432–437Google Scholar
  19. Miller LG, Greenblatt DJ, Paul SM, Shader RI (1987a) Benzodiazepine receptor occupancy in vivo: correlation with brain concentrations and pharmacodynamic actions. J Pharmacol Exp Ther 240:516–522Google Scholar
  20. Miller LG, Friedman H, Greenblatt DJ (1987b) Measurement of clonazepam by electron-capture gas-liquid chromatography with application to single-dose pharmacokinetics. J Anal Toxicol 11:55–57Google Scholar
  21. Miller LG, Greenblatt DJ, Barnhill JG, Summer WR, Shader RI (1988) GABA shift in vivo: enhancement of benzodiazepine binding in vivo by modulation of endogenous GABA. Eur J Pharmacol 148:123–130Google Scholar
  22. Möhler H, Okada T, Enna SJ (1978) Benzodiazepine and neurotransmitter receptor binding in rat brain after chronic administration of diazepam or phenobarbital. Brain Res 15:391–395Google Scholar
  23. Quast U, Mählmann H, Vollmer K-O (1982) Temperature dependence of the benzodiazepine-receptor interaction. Mol Pharm 22:20–25Google Scholar
  24. Rosenberg HC, Chiu TH (1979) Decreased [3H]-diazepam binding is a specific response to chronic benzodiazepine treatment. Life Sci 24:803–807Google Scholar
  25. Schliebs R, Rothe T, Bigh V (1983) Radioligand-Bindungsmessungen an beta-adrenergen und benzodiazepin-Rezeptoren in der Hirnrinde der Ratte. Biomed Biochim Acta 42:537–546Google Scholar
  26. Schultz DW, MacDonald RL (1981) Barbiturate enhancement of GABA-mediated inhibition and activation of chloride ion conductance: correlation with anticonvulsant and anesthetic actions. Brain Res 209:177–188Google Scholar
  27. Skolnick P, Rice KC, Barker JL, Paul SM (1982) Interaction of barbiturates with benzodiazepine receptors in the central nervous system. Brain Res 233:143–156Google Scholar
  28. Sonawane BR, Yaffe SJ, Shapiro BH (1980) Changes in mouse brain diazepam receptor binding after phenobarbital administration. Life Sci 27:1335–1338Google Scholar
  29. Study RE, Barker JL (1984) Diazepam and pentobarbital: fluctuation analysis reveals different mechanisms for potential of GABA responses in cultured central neurons. Proc Natl Acad Sci USA 78:7180–7184Google Scholar
  30. Ticku MK, Maksay G (1983) Convulsant/depressant site of action at the allosteric benzodiazepine-GABA-receptor-ionophore complex. Life Sci 33:2363–2375Google Scholar
  31. Toon S, Rowland M (1983) Structure-pharmacokinetic relationships among the barbiturates in the rat. J Pharmacol Exp Ther 225:752–763Google Scholar
  32. Toon S, Mayer J, Rowland M (1984) Liquid chromatographic determination of lipophilicity with application to a homologous series of barbiturates. J Pharm Sci 73:625–627Google Scholar

Copyright information

© Springer-Verlag 1988

Authors and Affiliations

  • Lawrence G. Miller
    • 1
  • Stephen I. Deutsch
    • 2
  • David J. Greenblatt
    • 1
  • Steven M. Paul
    • 2
  • Richard I. Shader
    • 1
  1. 1.Division of Clinical PharmacologyTufts University School of Medicine and New England Medical CenterBostonUSA
  2. 2.Clinical Neuroscience BranchNational Institute of Mental HealthBethesdaUSA

Personalised recommendations